ADARx Pharmaceuticals disclosed plans to raise about $319 million in a proposed IPO as it advances an siRNA program in Phase 3. The company is part of a broader IPO ramp in biopharma, with the filing expected to expand funding for late-stage clinical execution. Phase 3 siRNA development remains expensive and requires clear endpoints, manufacturing scale-up, and robust safety monitoring. By entering the market with an equity plan, ADARx is effectively betting that investors will value late-stage execution risk and the credibility of its clinical dataset. For the sector, the filing contributes to the growing set of late-stage biotechs seeking public capital ahead of potential catalyst windows in 2026.